Project Grant R01DA063157
- The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), awarded a $558,668 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the Massachusetts Institute of Technology (MIT) for the project "Integration and Validation of Single-Cell Neuronal and Immune Molecular Responses in SUD and HIV". The project aims to uncover the genetic and molecular mechanisms driving the interactions between HIV, neuropsychiatric, and...
- The National Institute on Drug Abuse (NIDA) awarded a $569,743 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Yale University on July 15, 2025. The grant, titled "Y-SCORCH 2.0: Further Data Mining and Functional Characterization for Single Cell Opioid Responses in the Context of HIV (SCORCH) Program," aims to leverage advanced tools to analyze transcriptomic and epigenetic data from the SCORCH consortium and novel spatial transcriptomic data to...
- This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will support a comprehensive effort to analyze hundreds of multi-omic datasets related to the impact of substance use disorders (SUD) and HIV on the brain's reward circuitry and neuroinflammation. The $556,432 award, commencing on September 1, 2025, will enable researchers at the University of Maryland, Baltimore to: Assemble a harmonized resource of...
- The National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $687,416 Project Grant to the J. David Gladstone Institutes in San Francisco, California. The grant is for a research project titled "Targeted Small Molecule Recruitment to Suppress the HIV Transcriptionally Active Reservoir" and runs from May 15, 2025 to March 31, 2030. The key objectives of this research project are to develop therapeutically effective...
- The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, awarded a $3,939,754 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the Northern California Institute for Research and Education, Inc. (NCIRE) for the "Stimulant and Polysubstance Use, Inflammation and Sex Effects on Myocardial Disease in HIV (SPISE)" research program. The goal of this 5-year project, beginning July 15, 2025, is to investigate the role of stimulant...
- The National Institute on Drug Abuse (NIDA), under CFDA Program 93.279 - Drug Use and Addiction Research Programs, awarded a $1 project grant to the J. David Gladstone Institutes. The grant aims to establish a novel mouse model for studying the impact of HIV and addictive substances on the central nervous system. Specifically, the project will develop a chimeric mouse model with human microglia, neurons, and astrocytes derived from induced pluripotent stem cells. This model will be used to...
- This $616,372 federal Project Grant was awarded on July 15, 2025 by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant supports research to identify neuronal, glial, and neural stem/progenitor cell transposable element (TE) transcriptional and epigenetic gene regulatory states involved in SIV, antiretroviral therapy, and cannabinoid exposure in a non-human primate model. Additionally, the research aims to identify TE expression...
- This Project Grant award from the National Institute on Drug Abuse (NIDA), part of the Department of Health and Human Services' Drug Use and Addiction Research Programs (CFDA 93.279), provides $147,486 to the Icahn School of Medicine at Mount Sinai to investigate the combined impact of HIV infection and nicotine use on neuroinflammation. The research aims to elucidate the role of the NLRP3 inflammasome in driving CNS inflammation, blood-brain barrier disruption, and viral reactivation in...
- This Project Grant award of $1,573,958 from the National Institute on Drug Abuse (NIDA), part of the Drug Use and Addiction Research Programs (CFDA 93.279), is focused on identifying individuals who are viremic and/or have substance use disorder (SUD) to engage them for early intervention. The project will implement routine SUD screening using the NIDA Quick Screen and a social network intervention to find individuals who are viremic, have SUD, or both, and link them to harm reduction and HIV...
- The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, awarded a $426,036 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Tulane University. The award will fund a study to examine the feasibility and acceptability of a virtual reality-based mindfulness intervention, called "TRIPP," to support people with comorbid HIV and substance use disorders. This population faces significant public health challenges, as substance...
The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), awarded a $608,652 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the Scripps Research Institute. The purpose of this 5-year award, with a start date of September 1, 2025, is to conduct data mining and functional validation of the Systematic Characterization of Retroviral Conditions for Health (SCORCH) datasets. The research aims to elucidate the key pathogenic mechanisms underlying the detrimental interactions between HIV, substance use disorder (SUD), and their effects on neuroinflammation, neurodegeneration, virus expression and persistence, and cognitive impairment. The project will utilize a validated systems biology strategy to reconstruct and interrogate gene regulatory networks from single-cell/single-nucleus RNA sequencing and chromatin accessibility data, with the goal of identifying novel therapeutic targets.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $608.7k | 8/8/25 |